1. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis 
Michael Kreuter, MD, David J. Lederer, MD, Maria Molina-Molina, MD, PhD, Imre Noth, MD, Claudia Valenzuela, MD, Lutz Frankenstein, MD, Derek Weycker, PhD, Mark Atwood, MS, Klaus-Uwe Kirchgaessler, MD, Vincent Cottin, MD, PhD 
CHEST 
DOI: /j.chest
Copyright © 2019 The Authors Terms and Conditions

2. Figure 1
A-D, Kaplan-Meier survival analysis of composite end point for disease progression and mortality by antihypertensive medication group. Disease progression (A) and all-cause mortality (B) in ACEi group vs non-ACEi/ARB group. Disease progression (C) and all-cause mortality (D) in ARB group vs non-ACEi/ARB group. aThe composite end point comprised the first occurrence of absolute decline in % predicted FVC ≥ 10%, 6MWD decline ≥ 50 m, or death from any cause. Only the first event was considered in the analysis. 6MWD = 6-min walk distance; ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; IPF = idiopathic pulmonary fibrosis.
CHEST DOI: ( /j.chest )
Copyright © 2019 The Authors Terms and Conditions

3. Figure 2
Hazard ratios for outcomes at 52 weeks by antihypertensive medication group; multivariable analysis. aThe composite end point comprised the first occurrence of absolute decline in % predicted FVC ≥ 10%, 6MWD decline ≥ 50 m, or death from any cause. Only the first event was considered in the analysis. bOnly confirmed cases were included, defined as those for whom follow-up assessment was repeated ≥ 6 weeks following initial assessment and criteria for the outcome were met. cDeath was treated as a competing risk. dHazard ratios were calculated using multivariable Cox proportional hazards models. en = 111, 121, and 392 patients in the ACEi, ARB, and non-ACEi/ARB groups, respectively. See Figure 1 legend for expansion of abbreviations.
CHEST DOI: ( /j.chest )
Copyright © 2019 The Authors Terms and Conditions